8-methoxy-4-methyl-quinazoline | 69674-28-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 8-methoxy-4-methyl-quinazoline
• 英文别名: 8-Methoxy-4-methyl-chinazolin；8-Methoxy-4-methylquinazoline
• CAS: 69674-28-8
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.202
• InChiKey: ZCGWGACIBYBGIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-methoxy-4-methyl-quinazoline 在 三氯化铝 作用下， 生成 4-methylquinazolin-8-ol
  参考文献：
  名称：

  具有另外的环状氮原子的8-羟基喹啉的类似物。第二部分 进一步的准备工作以及一些理化特性

  摘要：

  DOI：

  10.1039/jr9540000505
• 作为产物：
  描述：

  1-(2-氨基-3-甲氧基-苯基)-乙酮 在 乙酸铵 、 氨 作用下， 生成 8-methoxy-4-methyl-quinazoline
  参考文献：
  名称：

  具有另外的环状氮原子的8-羟基喹啉的类似物。第二部分 进一步的准备工作以及一些理化特性

  摘要：

  DOI：

  10.1039/jr9540000505

文献信息

• [EN] QUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS<br/>[FR] DÉRIVÉS DE QUINAZOLINE EN TANT QU'INHIBITEURS DE L'ENZYME PDE10A
  申请人：LUNDBECK & CO AS H

  公开号：WO2013050527A1

  公开（公告）日：2013-04-11

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  这项发明涉及一类PDE10A酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗患有药物成瘾的受试者的方法，包括向受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者施用式I化合物的治疗有效量。
• [EN] AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS<br/>[FR] DÉRIVÉS D'AMINO QUINAZOLINE SERVANT D'INHIBITEURS DE P2X3
  申请人：CHIESI FARM SPA

  公开号：WO2020239951A1

  公开（公告）日：2020-12-03

  The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

  本发明涉及抑制P2X嘌呤受体3的I式化合物；特别是涉及氨基喹唑啉衍生物的化合物，制备这种化合物的方法，含有它们的药物组合物以及它们的治疗用途。本发明的化合物可能在治疗与P2X3受体机制相关的许多疾病中有用，如呼吸道疾病，包括咳嗽、哮喘、特发性肺纤维化（IPF）和慢性阻塞性肺病（COPD）。
• Antihypertensive pyrrolo[1,2-c]quinazolines and pyrrolo[1,2-c]quinazolinones
  作者：Victor T. Bandurco、Elizabeth Malloy Wong、Seymour D. Levine、Zoltan G. Hajos

  DOI：10.1021/jm00144a017

  日期：1981.12

  The synthesis of a variety of pyrrolo[1,2-c]quinazolines and pyrrolo[1,2-c]quinazolinones is described. Several of these compounds have exhibited antihypertensive properties in the spontaneously hypertensive rat (SHR). Structure-activity comparisons have indicated that optimal activity is obtained in both the 2-carbethoxydihydroquinazoline series (C) and 2-carbethoxyquinazolinone series (D) when there

  描述了各种吡咯并[1,2-c]喹唑啉和吡咯并[1,2-c]喹唑啉酮的合成。这些化合物中的几种已在自发性高血压大鼠（SHR）中显示出降压特性。结构活性比较表明，当在位置6处有乙氧基或氰基乙基且苯环中没有取代基时，在2-carbethoxydihydroquinazoline系列（C）和2-carbethoxyquinazolinone系列（D）中均获得了最佳活性。当6-位和苯环均未被取代时，在2-甲基-喹唑啉酮系列（D）中可获得最佳活性。
• [EN] ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER<br/>[FR] INHIBITEURS D'ENPP1 ET LEUR UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2019051269A1

  公开（公告）日：2019-03-14

  Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.

  提供了用于抑制ENPP1的化合物、组合物和方法。所述方法的方面包括将样品与ENPP1抑制剂接触以抑制ENPP1的cGAMP水解活性。在某些情况下，ENPP1抑制剂是细胞不透过的。还提供了用于治疗癌症的组合物和方法。方法的方面包括向受试者施用治疗有效量的ENPP1抑制剂以治疗受试者的癌症。在某些情况下，癌症是实体肿瘤癌。还提供了在向受试者施用ENPP1抑制剂之前或之后进行放射治疗的方法。放射治疗可以以有效剂量和/或频率对受试者减少放射损伤。在某些情况下，该方法与化疗药物、或检查点抑制剂、或两者结合使用。
• [EN] IMINO SULFANONE INHIBITORS OF ENPP1<br/>[FR] INHIBITEURS IMINO SULFANONE DE L'ENPP1
  申请人：VOLASTRA THERAPEUTICS INC

  公开号：WO2021225969A1

  公开（公告）日：2021-11-11

  The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine- based inhibitors of ENPP1 of Formula (I) and methods of their use for treating disease mediated by ENPP1.

  本公开涉及一般来说是对细胞外核苷酸焦磷酸酶/磷酸二酯酶1（ENPP1）的抑制剂，其组合物以及使用所述化合物和组合物的方法。更具体地说，本公开涉及基于砜亚胺的ENPP1抑制剂，其化学式为（I），以及其用于治疗由ENPP1介导的疾病的方法。